NCT02347501View on ClinicalTrials.gov

Dipeptidyl Peptidase-4 Inhibition and Narrow-band Ultraviolet-B Light in Psoriasis (DINUP)

PHASE2CompletedINTERVENTIONAL

Enrollment

118

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions

Psoriasis

Interventions

DRUG

Sitagliptin (Januvia)

Sitagliptin 100mg tablet once daily (or 50mg once daily for participants with moderate kidney disease) for twenty four weeks in patients due to undergo NBUVB light therapy.

Trial Locations (1)

Unknown

UCD Clinical Research Centre, St Vincent's University Hospital, Dublin

All Listed Sponsors

lead

University College Dublin

OTHER

NCT02347501 - Dipeptidyl Peptidase-4 Inhibition and Narrow-band Ultraviolet-B Light in Psoriasis (DINUP) | Biotech Hunter | Biotech Hunter